Gara Jalqabaatti › Luukemiya Limfoositiikii Keessummaa › California › San Diego
Qorannoo klinikaalii Luukemiya Limfoositiikii Keessummaa San Diego, CA keessatti
Qorannoo 10 Luukemiya Limfoositiikii Keessummaa f San Diego fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- University of California San Diego (Ucsd) Moores Cancer Center, La Jolla · Miili 11 fagaatti
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Namoota walitti qabaa jiraSadarkaa 3
- Kaiser Permanente-San Diego Zion, San Diego
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Namoota walitti qabaa jiraSadarkaa 3
- Kaiser Permanente-San Diego Zion, San Diego
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, La Jolla · Miili 11 fagaatti
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Namoota walitti qabaa jiraSadarkaa 3
- Scripps Prebys Cancer Center, San Diego
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Namoota walitti qabaa jiraSadarkaa 3
- Scripps Prebys Cancer Center, San Diego
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Namoota walitti qabaa jiraSadarkaa 3
- University of California San Diego (Ucsd) Moores Cancer Center, La Jolla · Miili 11 fagaatti
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Namoota walitti qabaa jiraSadarkaa 3
- Moores Cancer Center ( Site 0003), La Jolla · Miili 11 fagaatti
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Namoota walitti qabaa jiraSadarkaa 2
- Scripps Health, San Diego
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Namoota walitti qabaa jiraSadarkaa 2
- Moores Cancer Center at UC San Diego /ID# 230157, La Jolla · Miili 11 fagaatti
Qorannoo Luukemiya Limfoositiikii Keessummaa magaalota biroo keessatti
- Boston, MAQorannoo 31
- Columbus, OHQorannoo 28
- Durham, NCQorannoo 27
- Washington, DCQorannoo 22
- Seattle, WAQorannoo 20
- Rochester, MNQorannoo 18
- New York City, NYQorannoo 18
- Houston, TXQorannoo 17
- Baldwin Park, CAQorannoo 16
- Milwaukee, WIQorannoo 15
- Chicago, ILQorannoo 14
- Cincinnati, OHQorannoo 14
Qorannoo biroo San Diego keessatti
- Kansara Qara'a Non-Small CellQorannoo 48
- Saree OljooQorannoo 41
- Saree (Gosoota Hunda)Qorannoo 32
- Kansarii ProstateQorannoo 31
- Kansara MetastatikiiQorannoo 30
- Kansarii ColorectalQorannoo 25
- Kansarii OvariiQorannoo 24
- Kansarii PancreasQorannoo 24
- Dhibee QaraQorannoo 23
- ObesityQorannoo 23
- Cufama OnneeQorannoo 23
- DepreshiniiQorannoo 21
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.